Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Status:
Completed
Trial end date:
2018-07-06
Target enrollment:
Participant gender:
Summary
Primary objective of the trial is to evaluate the safety of afatinib in patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR (Epidermal growth
factor receptor) mutation(s) and have never been treated with an EGFR-TKI (tyrosine kinase
inhibitor). Secondary objective is to assess the time to symptomatic progression (as judged
by investigator).